Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication

NCT02624167 is registered in ClinicalTrials.gov with Newron Pharmaceuticals SPA as lead sponsor.

NCT NCT02624167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02624167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication
Lead sponsor
Newron Pharmaceuticals SPA
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2015
Completion date
January 31, 2017
Enrollment
90 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic schizophrenia